Compare WYY & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WYY | NSPR |
|---|---|---|
| Founded | 1991 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 48.1M | 72.1M |
| IPO Year | 2005 | 2009 |
| Metric | WYY | NSPR |
|---|---|---|
| Price | $5.21 | $1.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $8.67 | $4.00 |
| AVG Volume (30 Days) | 32.6K | ★ 44.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,545,364.00 | $2,310,000.00 |
| Revenue This Year | $14.41 | $57.98 |
| Revenue Next Year | $11.41 | $95.41 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.59 | N/A |
| 52 Week Low | $2.71 | $1.28 |
| 52 Week High | $7.55 | $2.93 |
| Indicator | WYY | NSPR |
|---|---|---|
| Relative Strength Index (RSI) | 53.40 | 32.05 |
| Support Level | $4.95 | N/A |
| Resistance Level | $5.85 | $2.50 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 80.41 | 14.69 |
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.